AnaptysBio (ANAB)
(Delayed Data from NSDQ)
$35.71 USD
+2.01 (5.96%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $35.72 +0.01 (0.03%) 6:52 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
AnaptysBio, Inc. (ANAB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$43.60 | $80.00 | $20.00 | 29.38% |
Price Target
Based on short-term price targets offered by 10 analysts, the average price target for AnaptysBio, Inc. comes to $43.60. The forecasts range from a low of $20.00 to a high of $80.00. The average price target represents an increase of 29.38% from the last closing price of $33.70.
Analyst Price Targets (10)
Broker Rating
AnaptysBio, Inc. currently has an average brokerage recommendation (ABR) of 1.36 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 11 brokerage firms. The current ABR compares to an ABR of 1.55 a month ago based on 11 recommendations.
Of the 11 recommendations deriving the current ABR, nine are Strong Buy, representing 81.82% of all recommendations. A month ago, Strong Buy represented 72.73%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 9 | 8 | 8 | 8 | 8 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.36 | 1.55 | 1.55 | 1.55 | 1.55 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/17/2024 | Piper Sandler | Yasmeen Rahimi | Strong Buy | Strong Buy |
4/16/2024 | SVB Securities | David Risinger | Not Available | Strong Buy |
4/11/2024 | Wells Fargo Securities | Derek C Archila | Not Available | Strong Buy |
4/1/2024 | Cowen & Co. | Joseph Thome | Strong Buy | Strong Buy |
3/18/2024 | Truist Securities | Joon Lee | Hold | Hold |
3/12/2024 | Wedbush Securities | David M Nierengarten | Strong Buy | Strong Buy |
2/26/2024 | BTIG | Julian Harrison | Not Available | Strong Buy |
2/21/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
1/12/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
11/1/2023 | UBS | Eliana Merle | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.36 |
ABR (Last week) | 1.55 |
# of Recs in ABR | 11 |
Average Target Price | $43.60 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 71 of 252 |
Current Quarter EPS Est: | -1.08 |